Soleno Therapeutics Inc [SLNO] stock is trading at $71.45, down -0.75%. An important factor to consider is whether the stock is rising or falling in short-term value. The SLNO shares have gain 42.50% over the last week, with a monthly amount glided 46.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stifel reaffirmed its Buy rating on December 02, 2024, and kept the price target unchanged to $74. On December 02, 2024, Robert W. Baird reiterated its Outperform rating but maintained its price target of $72 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $70 on September 03, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $72 as its price target on May 10, 2024. Piper Sandler started tracking with a Overweight rating for this stock on February 05, 2024, and assigned it a price target of $93. In a note dated January 23, 2024, Stifel initiated an Buy rating and provided a target price of $63 on this stock.
Soleno Therapeutics Inc [SLNO] stock has fluctuated between $36.61 and $73.97 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $71.45 at the most recent close of the market. An investor can expect a potential return of 4.97% based on the average SLNO price forecast.
Analyzing the SLNO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.75 and Total Capital is -0.59. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 69.57 points at the first support level, and at 67.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 73.64, and for the 2nd resistance point, it is at 75.82.
Ratios To Look Out For
For context, Soleno Therapeutics Inc’s Current Ratio is 15.68. On the other hand, the Quick Ratio is 15.68, and the Cash Ratio is 4.69.
Transactions by insiders
Recent insider trading involved Pauls Matthew, Director, that happened on Mar 28 ’25 when 5937.0 shares were sold., Yen Kristen completed a deal on Mar 27 ’25 to sell 95500.0 shares. Meanwhile, Chief Commercial Officer Manning Meredith sold 45249.0 shares on Mar 27 ’25.
